Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma

Simple Summary The evaluation of tumor response to anti-cancer therapy is critical in oncology for the prompt determination of subsequent treatment and follow-up strategies. Historically, response criteria have been based on tumor size changes; however, since the development of locoregional and molecular-targeted therapies in HCC (which act by disrupting tumor vascularization rather than tumor cells), changes in tumor vascularity and enhancement patterns have been considered to be more reliable. Contrast-enhanced ultrasound (CEUS) and dynamic CEUS, which allow microvessel perfusion studies, are emerging as promising tools for early tumor response evaluation. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure at different stages of the disease. Abstract The capacity of contrast-enhanced ultrasound (CEUS) to detect microvessel perfusion has received much attention in cancer imaging since it can be used to evaluate the enhancement patterns of the lesions during all vascular phases in real time, with higher temporal resolution as compared other imaging modalities. A rich body of literature has demonstrated the potential usefulness of CEUS in the assessment of HCC in response to both locoregional and systemic therapies. It is useful to evaluate the efficacy of ablation immediately after treatment to provide guidance for the retreatment of residual unablated tumors. In patients treated with transarterial chemoembolization (TACE), CEUS showed a high degree of concordance with computed tomography and magnetic resonance for the differentiation of responders from non-responders. Dynamic CEUS (D-CEUS) has emerged as a promising tool for the depicting changes in tumor perfusion during anti-angiogenetic treatment that can be associated with tumor response and clinical outcome. This article provides a general review of the current literature regarding the usefulness of CEUS in monitoring HCC response to therapy, highlighting the role of the procedure in different stages of the disease.

[1]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[2]  Manabu Watanabe,et al.  Predicting Therapeutic Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound , 2021, Diagnostics.

[3]  L. Alecu,et al.  Heterogeneity of antigenic constellation in human hepatocellular carcinoma. , 2021, Experimental and therapeutic medicine.

[4]  A. Lyshchik,et al.  Contrast-enhanced Ultrasound Identifies Patent Feeding Vessels in Transarterial Chemoembolization Patients With Residual Tumor Vascularity , 2020, Ultrasound quarterly.

[5]  Wei Yang,et al.  The Perfusion Features of Recurrent Hepatocellular Carcinoma After Radiofrequency Ablation Using Contrast-Enhanced Ultrasound and Pathological Stemness Evaluation: Compared to Initial Tumors , 2020, Frontiers in Oncology.

[6]  Jae Young Lee,et al.  Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. , 2020, Ultrasound in medicine & biology.

[7]  K. Malagari,et al.  Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography , 2020, CardioVascular and Interventional Radiology.

[8]  M. Moriyama,et al.  Utility of Contrast‐Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization , 2019, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[9]  A. Gasbarrini,et al.  Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment , 2020, Digestive Diseases.

[10]  W. Cheng,et al.  Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study , 2020, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[11]  E. Jung,et al.  Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma , 2019, PloS one.

[12]  Hiroki Sato,et al.  Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma , 2019, World journal of gastroenterology.

[13]  R. Bale,et al.  Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers , 2019, Hepatology.

[14]  M. Huang,et al.  Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following Transarterial Chemoembolization: Is It Helpful for Tumor Response? , 2018, BioMed research international.

[15]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[16]  Y. Kono,et al.  Evaluation of hepatocellular carcinoma transarterial chemoembolization using quantitative analysis of 2D and 3D real-time contrast enhanced ultrasound , 2018, Biomedical physics & engineering express.

[17]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[18]  X. Cui,et al.  EFSUMB Guidelines on Interventional Ultrasound (INVUS), Part III – Abdominal Treatment Procedures (Long Version) , 2015, Ultraschall in der Medizin.

[19]  Wei Zhang,et al.  Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. , 2015, World journal of gastroenterology.

[20]  Ming-de Lu,et al.  Role of portal vein tumor thrombosis in quantitative perfusion analysis of contrast-enhanced ultrasound of hepatocellular carcinoma. , 2015, Ultrasound in medicine & biology.

[21]  K. McGlynn,et al.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. , 2015, Clinics in liver disease.

[22]  D. Merton,et al.  Contrast‐Enhanced Ultrasound Evaluation of Residual Blood Flow to Hepatocellular Carcinoma After Treatment With Transarterial Chemoembolization Using Drug‐Eluting Beads , 2015, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[23]  Ming-de Lu,et al.  Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST , 2015, European Radiology.

[24]  Nathalie Lassau,et al.  Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors , 2014, Investigative radiology.

[25]  V. Pannain,et al.  Microvascular density of regenerative nodule to small hepatocellular carcinoma by automated analysis using CD105 and CD34 immunoexpression , 2014, BMC Cancer.

[26]  N. Kelekis,et al.  mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization. , 2013, Diagnostic and interventional radiology.

[27]  A. Gasbarrini,et al.  Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. , 2013, Journal of hepatology.

[28]  M. Okada,et al.  Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. , 2013, European journal of radiology.

[29]  C. Bartolozzi,et al.  Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. , 2013, European journal of radiology.

[30]  Nathalie Lassau,et al.  Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. , 2013, European journal of radiology.

[31]  L. Bolondi,et al.  Characterization of Primary and Recurrent Nodules in Liver Cirrhosis Using Contrast-Enhanced Ultrasound: Which Vascular Criteria Should Be Adopted? , 2013, Ultraschall in der Medizin.

[32]  Y. Imai,et al.  Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast‐enhanced US , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[33]  Hui-Xiong Xu,et al.  Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma. , 2013, World journal of gastroenterology.

[34]  S. Lazzaroni,et al.  Contrast enhanced ultrasound: Should it play a role in immediate evaluation of liver tumors following thermal ablation? , 2012, European journal of radiology.

[35]  C. Dietrich,et al.  An EFSUMB Introduction into Dynamic Contrast-Enhanced Ultrasound (DCE-US) for Quantification of Tumour Perfusion , 2012, Ultraschall in der Medizin.

[36]  J. Bruix,et al.  Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. , 2012, Journal of hepatology.

[37]  K. Stamatiou,et al.  Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. , 2012, Medical ultrasonography.

[38]  K. Malagari,et al.  Short-term evaluation of liver tumors after transarterial chemoembolization: limitations and feasibility of contrast-enhanced ultrasonography , 2011, Abdominal Imaging.

[39]  K. Malagari,et al.  Unenhanced and Contrast-Enhanced Ultrasonography During Hepatic Transarterial Embolization and Chemoembolization With Drug-Eluting Beads , 2010, CardioVascular and Interventional Radiology.

[40]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[41]  Sukru Mehmet Erturk,et al.  Is Contrast-Enhanced US Alternative to Spiral CT in the Assessment of Treatment Outcome of Radiofrequency Ablation in Hepatocellular Carcinoma? , 2009, Ultraschall in der Medizin.

[42]  Kinuyo Hatanaka,et al.  Response Evaluation of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinomas: The Usefulness of Sonazoid-Enhanced Harmonic Sonography , 2008, Oncology.

[43]  Xiao-Ling Yu,et al.  Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. , 2007, Ultrasound in medicine & biology.

[44]  Linda Chami,et al.  Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. , 2006, AJR. American journal of roentgenology.

[45]  Linda Chami,et al.  To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. , 2006, European journal of cancer.

[46]  P. Burns,et al.  Radiofrequency ablation of hepatocellular carcinoma: predicting success using contrast-enhanced sonography. , 2006, AJR. American journal of roentgenology.

[47]  Luigi Solbiati,et al.  Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. , 2004, European journal of radiology.

[48]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[49]  D. Sze,et al.  Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2012, Journal of vascular and interventional radiology : JVIR.

[50]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[51]  Donald L. Miller,et al.  Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. , 2012, Journal of vascular and interventional radiology : JVIR.